Cargando...
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from init...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2858493/ https://ncbi.nlm.nih.gov/pubmed/20197552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-233304 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|